Asian Journal of Research and Reports in Neurology

Egypt Fights Spinal Muscular Atrophy

Omar Elsaka *

Faculty of Medicine, Mansoura University, Mansoura Manchester Medical Program (MMMP), Mansoura, Egypt.

Moneer Ayman Noureldean

Faculty of Medicine, Mansoura University, Mansoura Manchester Medical Program (MMMP), Mansoura, Egypt.

Mohamed Adel Gamil

Faculty of Medicine, Mansoura University, Mansoura Manchester Medical Program (MMMP), Mansoura, Egypt.

Mostafa Tarek Ghazali

Faculty of Medicine, Mansoura University, Mansoura Manchester Medical Program (MMMP), Mansoura, Egypt.

Ashraf Hamada Abd Al-Razik

Faculty of Medicine, Mansoura University, Mansoura Manchester Medical Program (MMMP), Mansoura, Egypt.

Dalia Hisham

Faculty of Medicine, Mansoura University, Mansoura Manchester Medical Program (MMMP), Mansoura, Egypt.

*Author to whom correspondence should be addressed.

---

Abstract

SMA (spinal muscular atrophy) is a neuromuscular illness caused by a genetic (inherited) mutation that causes muscles to weaken and waste away. Motor neurons, a type of nerve cell in the spinal cord that controls muscle movement, are lost in people with SMA. Many pharmaceutical companies continue to invest heavily in research into SMA therapies. Many additional prospective medications, such as valproic acid, phenylbutyrate, hydroxyurea, albuterol, gabapentin, riluzole, olesoxime, and rapamycin, have failed to generate adequate outcomes regarding disease progression.

Keywords: Spinal muscular atrophy, medications, hydroxyurea, neuromuscular illness.

---

---